Abstract Number: 444 • 2012 ACR/ARHP Annual Meeting
Tocilizumab Improves Bone Mineral Density Compared with Abatacept in Patients with TNF Blockers-Resistant Active Rheumatoid Arthritis. an Open Label Randomized Controlled Trial
Background/Purpose: To compare the effect of tocilizumab(TCZ) plus methotrexate (MTX), with the effect of abatacept(ABT) plus MTX on bone mineral density(BMD) in TNF blockers resistant…Abstract Number: 2465 • 2012 ACR/ARHP Annual Meeting
Seroresponse Rates After Influenza Vaccination in Rheumatoid Arthritis Patients Treated with Biological Agents During the 2011–2012 Flu Season
Background/Purpose: At present, annual vaccination against influenza is recommended for rheumatoid arthritis (RA) patients. However, whether humoral responses to influenza vaccine are impaired in RA…Abstract Number: 350 • 2012 ACR/ARHP Annual Meeting
Reduction of Inflammation with Abatacept and Tocilizumab Results in Lower N-Terminal Pro Brain Natriuretic Peptide Levels in Patients with Rheumatoid Arthritis: Results From Prospective Cohort Studies
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk of heart failure (HF). The chronic inflammatory state in RA is associated with increased levels of…Abstract Number: 2163 • 2012 ACR/ARHP Annual Meeting
Abatacept Monotherapy Effectively Reduces the Frequency of Osteoclast Precursor Cells in the Peripheral Blood of Patients with Rheumatoid Arthritis and Inhibits Their Differentiation Into Osteoclasts
Background/Purpose: Bone resorbing osteoclasts origin from monocytes. We have recently shown that binding of abatacept (CTLA4-Ig) to CD80 and CD86 on the surface of monocytes…Abstract Number: 289 • 2012 ACR/ARHP Annual Meeting
Mycophenolate Mofetil and Abatacept Combination Therapy in Refractory Pediatric Systemic Lupus Erythematosus Nephritis
Background/Purpose: Nephritis (LN) in pediatric systemic lupus erythematosus (pSLE) requires treatment (tx) with corticosteroids (CS) and other agents such as mycophenolate mofetil (MMF) or cyclophosphamide…Abstract Number: 1923 • 2012 ACR/ARHP Annual Meeting
Biologics in Relapsing Polychondritis: A Single Center Case-Series
Background/Purpose: First-line treatment for relapsing polychondritis (RP) is costicosteroids (CS). Dapsone and methotrexate have been proposed as second-line therapies. Only few reports have been published…Abstract Number: 275 • 2012 ACR/ARHP Annual Meeting
Pediatric Rheumatology Practitioners Experience with Biologics in Juvenile Dermatomyositis: Survey Results
Background/Purpose: Biologic therapy is increasingly prescribed in rheumatologic disorders. Juvenile dermatomyositis (JDM), the most common inflammatory myopathy in children, can be challenging to manage in…Abstract Number: 1679 • 2012 ACR/ARHP Annual Meeting
Cumulative Long-Term Safety and Efficacy of Abatacept in Children with Juvenile Idiopathic Arthritis: Results up to 7 Years of Follow-up
Background/Purpose: We previously reported the efficacy and safety of abatacept (ABA) in patients with juvenile idiopathic arthritis (JIA) in the AWAKEN trial1, during the 4-month…Abstract Number: 5 • 2012 ACR/ARHP Annual Meeting
Adalimumab Inhibits TNF-Enhanced Human Osteoclast Development More Effectively Than Other Biologic Agents Under in Vitro Conditions of Chronic TNF Exposure
Background/Purpose: TNF-alpha (TNFa) has been shown to contribute to osteoclastogenesis independently and in conjunction with M-CSF or RANKL, two key cytokines involved in osteoclast development. …Abstract Number: 1695 • 2012 ACR/ARHP Annual Meeting
Prolonged Exposure to Subcutaneous and Intravenous Abatacept in Patients with Rheumatoid Arthritis Does Not Affect Rates of Infection, Malignancy and Autoimmune Events: Results From Pooled Clinical Trial Data
Background/Purpose: Disease-modifying therapies for RA have proven efficacy, but these drugs may have selective toxicities, such as malignancy, that may increase with duration of treatment.…Abstract Number: 1655 • 2012 ACR/ARHP Annual Meeting
An Open-Label Trial of Abatacept in Mild Relapsing Granulomatosis with Polyangiitis (Wegener’s)
Background/Purpose: Granulomatosis with polyangiitis (Wegener's, GPA) is a primary systemic vasculitis that carries a high predilection for relapse. An area of unmet need has been…Abstract Number: 1340 • 2012 ACR/ARHP Annual Meeting
Effects of Subcutaneous Abatacept or Adalimumab On Remission and Associated Changes in Physical Function and Radiographic Outcomes: One Year Results From the Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) Trial
Background/Purpose: Advancements in the understanding of Rheumatoid Arthritis (RA) have led to the development of novel therapeutics and treatment guidelines that target remission as an…
- « Previous Page
- 1
- …
- 10
- 11
- 12